Clinical trial
A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study
NCT05438043 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- December 15, 2022
- Completion date
- January 31, 2029
- Enrollment
- 213 (actual)
- Sites
- 92
Conditions
As the registry lists them; a condition with its own page is linked.